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Abstract
Endolymphatic sac tumor (ELST) is a rare neoplasm which can be encountered sporadically or in Von Hippel-
Lindau (VHL) disease. Here we report a sporadic case of ELST in 31-year-old man. Neither the symptoms nor a
family history of VHL disease were found in the patient. CT imaging demonstrated an expansile lytic lesion of the
mastoid process of the left petrous bone. MR scanning revealed a 5.2 cm × 4.7 cm × 4.2 cm mass which showed
hyperintensity on T1- and T2-weighted images. Histologic sections showed a papillary, cystic or glandular
architecture. The papillary and glandular structures were lined by a single layer of flattened cuboidal-to-columnar
cells. The stroma of the papillary fronds was richly vascularized and chronically inflamed. The tumor showed
diffusely positive reactivity with cytokeratin (Pan), cytokeratin 19, cytokeratin 5/6, cytokeratin 7, EMA, vimentin,
CD56, and NSE and also showed variable reactivity with glial fibrillary acidic protein (GFAP) and VEGF. The Ki-67
immunostain showed a proliferation index of < 1%. Because the mass was large, it was difficult to extirpate
surgically. After surgery, the patient underwent gamma-knife radiosurgery for residual tumor. The findings indicate
that ELST is a rare neoplasm with benign histopathological appearance and clinically destructive behavior. Because
of the rarity of this tumor, it can easily be confused with other tumors such as paraganglioma, middle ear
adenoma, adenocarcinoma, papillary carcinoma of thyroid or choroid plexus papilloma. Owing to its locally
aggressive nature, it is difficult to extirpate surgically when it is large.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/7973320646763012
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Background
Endolymphatic sac tumor (ELST) is a rare neoplasm
with benign histopathological appearance and clinically
destructive behavior which occurs in the skull base and
frequently invades the posterior petrous bone, the mas-
toid, semicircular canal, cerebellopontine angle struc-
tures and cranial nerve. It is synonymous with Heffner
tumor, low grade adenocarcinoma of endolymphatic sac
origin, and aggressive papillary middle ear tumor
according to the recently published World Health Orga-
nization tumor classification. These tumors can be
encountered sporadically or in Von Hippel-Lindau
(VHL) disease. Because of the rarity of this tumor, it
can easily be confused with other tumors such as para-
ganglioma, middle ear adenoma, adenocarcinoma, papil-
lary carcinoma of thyroid or choroid plexus papilloma.
This report presents a 31-year-old male patient with
endolymphatic sac tumor who was initially diagnosed
with paraganglioma, with the following objectives: 1) to
improve understanding of the variable clinical presenta-
tion of endolymphatic sac tumor, and 2) to identify his-
tomorphological and immunohistochemical features of
endolymphatic sac tumor.
Case presentation
Clinic history
The patient presented with a chief complaints of pro-
gressive hearing loss of approximately 4-year duration.
In the past month, the symptom increased accompa-
nied by headaches. There was no tinnitus, otalgia,
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no history of trauma or surgeries. On physical exami-
nation, the hearing of left ear disappeared. The right
ear was normal. Examination of the facial nerves, naso-
pharynx, oral cavity, larynx and neck was normal.
Neither the symptoms nor a family history of VHL dis-
ease were found in the patient. Computed tomography
(CT) demonstrated a large, hypodense, and expansile
lytic lesion of the mastoid process of the left petrous
bone extending to involve both the left medial mastoid
as well as the middle ear (Figure 1A). Magnetic reso-
nance (MR) revealed a 5.2 cm × 4.7 cm × 4.2 cm mass
in the mastoid process of the left petrous bone which
was irregular, heterogeneous, and lobulated and
showed hyperintensity on T1- and T2-weighted images
( F i g u r e1 B ) .T h ep e r i p h e r yo ft h el e s i o na p p e a r e d
markedly hyperintense on the T2-weighted images
(Figure 1C). This might represent hemorrhage (extra-
cellular methemoglobin) or cystic areas with high pro-
tein within the lesion. Axial postcontrast T1-weighted
MR scan showed a heterogeneous enhancing mass
(Figure 1D). Surgical excision was performed. Because
the mass was too large, it was difficult to extirpate sur-
gically. After surgery, the patient underwent gamma-
knife radiosurgery for residual tumor.
Materials and methods
Formalin-fixed, paraffin-embedded tissues from the
ELST was available. These were routinely processed and
stained with hematoxylin and eosin (H&E). In addition
Figure 1 Radiologic characterization of endolymphatic sac tumor. A. CT imaging demonstrated an expansile lytic lesion of the mastoid
process of the left petrous bone extending to involve both the left medial mastoid as well as the middle ear. B. MR scan showed a 5.2 cm ×
4.7 cm × 4.2 cm mass which was irregular, heterogeneous, and lobulated and showed hyperintensity on T1-weighted images. C. The periphery
of the lesion appeared markedly hyperintense on the T2-weighted images. D. Axial postcontrast T1-weighted MR scan showed a heterogeneous
enhancing mass.
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acid-Schiff (PAS).
An immunohistochemical study was performed by
EnVision method. The antibodies used were cytokeratin
(Pan), epithelial membrane antigen (EMA), cytokeratin
19, cytokeratin 5/6, cytokeratin 7, vimentin, CD56, glial
fibrillary acidic protein (GFAP), NSE, VEGF, S-100,
CgA, Syn, TTF-1, thyroglobulin, calretinin and Ki-67
(DakoCytomation, Glostrup, Denmark). For antigen
retrieval, slides were boiled with citrate buffer (0.01
mol/L, pH6.0) under high pressure for all the antigens.
Appropriate positive and negative control experiments
were performed.
Pathological findings
Grossly, the specimen was received as an aggregate of
pale pink fragments that were noted to be moderate in
consistency. It was 5 cm × 4 cm × 2 cm in size.
Morphologically, the tumor showed a papillary, cystic
or glandular architecture. And the growth pattern was
invasive, with destruction of petrous bone. On higher
magnification the papillary and glandular structures
were lined by a single layer of flattened cuboidal-to-
columnar cells (Figure 2A). The stroma of the papillary
fronds was richly vascularized and chronically inflamed
(Figure 2B). The epithelial cells had uniform nuclei that
were usually situated either in the cell center or toward
the luminal aspect. They had a pale eosinophilic to clear
cytoplasm (Figure 2C). Cell borders may be seen, but
neoplastic cells may lack a distinct cell membrane.
There were minimal cellular pleomorphism and rare
mitotic activity and necrosis was not observed. There
were cystic glandular spaces filled with colloid-like
material which was remarkably similar to thyroid tissue
(Figure 2D).
Immunohistochemical findings
The tumor showed diffusely positive reactivity with
cytokeratin (Pan) (Figure 3A), cytokeratin 19, cytokera-
tin 5/6, cytokeratin 7, EMA, vimentin (Figure 3B), CD56
(Figure 3C), and NSE (Figure 3D) and also showed vari-
able reactivity with GFAP and VEGF. Thyroglobulin,
TTF-1, S-100, and calretinin immunoreactivity was not
observed. The Ki-67 immunostain showed a prolifera-
tion index of < 1%. The colloid-like material showed
positive reactivity with PAS.
Discussion
Endolymphatic sac tumor is a primary neoplasm of the
temporal bone which is described in patients as young
as 4 years and as old as 85 years [1-8]. Mean age of
patients without VHL disease was 52.5 years, whereas in
46 patients with VHL disease the mean age was 31.3
years. Patients with VHL disease were more likely to be
female (female-to male ratio of 2:1 for VHL disease
patients versus 1:1 for non- VHL disease patients) [2].
Patients characteristically present with unilateral sensor-
ineural hearing loss, tinnitus, otalgia, otorrhea, vertigo,
ataxia, and facial nerve paresis. Meniere syndrome is
uncommon. Large tumors growing along the posterome-
dial vector may cause symptoms secondary to cerebello-
pontine angle invasion. An indolent clinical course and
long-standing symptom history are typical. The imaging
hallmark of ELST is the presence of a retrolabyrinthine
mass associated with osseous erosion. CT imaging
demonstrated an expansile lytic lesion of the mastoid
process of the petrous bone which extended to involve
both the posterior fossa as well as the middle ear. In
some case, the core of the tumor appeared isointense
with brain on both the T1- and T2-weighted images
with slight enhancement after intravenous gadolinium
[9]. Our case showed hyperintensity on T1- and T2-
weighted images and axial postcontrast T1-weighted
MR scan showed a heterogeneous enhancing mass. The
periphery of the lesion appeared markedly hyperintense
on the T2-weighted images. This might represent
hemorrhage (extracellular methemoglobin) or cystic
areas with high protein within the lesion.
Endolymphatic sac tumors are known to occur more
frequently in patients with VHL disease, with up to 16
percent of patients with VHL disease harboring an
ELST [10] Patients with VHL disease are more likely to
have bilateral ELSTs. VHL disease is an autosomal
dominant syndrome due to deletions or mutations in
the VHL gene located on short arm of chromosome 3
(3p25-p26) [11]. The normal VHL gene is a tumor sup-
pressor gene and it seems likely that the diminution of
tumor suppression activity which results from the muta-
tion of that gene leads to the various manifestations of
the disease: renal cysts and renal carcinoma, pheochro-
mocytoma, pancreatic cysts, neuroendocrine tumors,
cystadenomas of the reproductive adnexal organs, and
hemangioblastomas of the cerebellum, spinal cord, brain
stem, and retina. VHL gene mutations have been shown
both in ELSTs associated with VHL disease and in
sporadic cases. Gene analysis performed to a patient
with ELST who presented with a medical and family
h i s t o r yo fV H Ld i s e a s es h o w e dm u t a t i o ni nV H Lg e n e ,
resulting in C to T exchange at position 194, the conse-
quence of which is an amino acid exchange S65L [3].
Sporadic cases of endolymphatic sac tumor without
VHL disease also showed VHL gene mutation similar to
that in the germ line of patients with the disease accord-
ing to Hamazaki’s study [12].
The origin of endolymphatic sac tumors remains con-
troversial for many years. Several reports mentioned the
mastoid or middle ear epithelium as origin of these
tumors [4,13,14]. Only recently, convincing anatomic,
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exist for an endolymphatic sac origin (inner-ear origin).
The tumor was first identified during sac decompression
surgery in 1984 [15]. In 1989 Heffner described a new
pathological entity of the endolymphatic sac. This tumor
grew slowly, destroyed the temporal bone, and showed
papillary cystic and glandular patterns. He also found
the epicenters of the tumors in his cases and in other
reports to have the same anatomic location, in the area
of the vestibular aqueduct and endolymphatic sac of the
posterior petrous bone. In addition, there are some
common histologic features between these tumors and
the normal endolymphatic sac. So he speculated that the
tumor arise in the endolymphatic sac [16]. In 2004 Lon-
ser described a 40-year-old man with von Hippel Lindau
disease showing bilateral endolymphatic sac tumors. On
the right side there was an extensive endolymphatic sac
tumor invading the temporal bone to involve structures
as far distant as mastoid air cells. On the left side illus-
trations define a papillary tumor confined to the lumen
of endolymphatic ducts and sacs (EDS), extending from
the endolymphatic duct to the extraosseous sac on the
dural surface. This case described here confirms the
concept of an origin of the neoplasm in the endolym-
phatic sac [17]. The endolymphatic duct arises in the
posteroinferior part of the vestibule of the inner ear as
the result of the union of an endolymph-containing
epithelial tube from the saccule and one from the utri-
cle. This tube passes into a bony canal, the vestibular
aqueduct, and extends posteriorly and laterally. It soon
widens in a superior-inferior plane but not in an antero-
posterior one, and is here known as the endolymphatic
sac. A study of the epithelium of normal human mature
endolymphatic ducts and sacs (EDSs) in archival tem-
poral bone sections showed hyperplastic tubular out-
growths, usually situated in the intraosseous portion of
the endolymphatic sac, in most cases. So the intraoss-
eous portion of the endolymphatic sac maybe the the
origin of endolymhoatic sac tumor [18]. The endolym-
phatic sac is derived from neuroectoderm and is located
subjacent to the posteromedial surface of the temporal
bone. There are 4 potential vectors for endolymphatic
Figure 2 Histopathologic characterization of endolymphatic sac tumor. A. Histologic sections showed a papillary architecture (H&E, 100×).
B. The stroma of the papillary fronds was richly vascularized(H&E, 200×). C. The papillary structures were lined by a single layer of flattened
cuboidal-to-columnar cells. There were minimal cellular pleomorphism and rare mitotic activity (H&E, 400×). D. There were cystic glandular
spaces filled with colloid-like material which was remarkably similar to thyroid tissue (H&E, 200×).
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pontine angle, laterally toward the middle ear, superiorly
toward the middle cranial fossa, and anteromedially
along the petrous ridge toward the cavernous and sphe-
noid sinuses. Individual examples may grow primarily
along one of these vectors or along multiple vectors
[19].
Histopathologically, these tumors are composed of
papillary and cystic proliferations lined by a single layer
of flattened cuboidal-to-columnar cells. The nuclei of
the epithelial layer show slight variability in size and
shape. Mitotic activity is rare. The stroma of the papil-
lary fronds was richly vascularized and chronically
inflamed. Large areas of hypocellular fibrosis, hemor-
rhage, cholesterol clefts, and associated reactive changes
are frequently found. Because of the rarity of this tumor,
that can easily be confused with other papillary lesions
on histopathologic grounds. The histopathological differ-
ential diagnosises of ELST include paraganglioma, chor-
ioid plexus papilloma, papillary ependymoma, papillary
mesohyloma, middle ear adenoma, and metastatic carci-
noma of the thyroid, kidney, prostate, lung, and breast.
Paragangliomas of the middle ear are cytologically
benign and may demonstrate papillary structures and
cuboidal cells with eosinophilic cytoplasm. However,
paraganglioma cells are positive for chromogranin and
synaptophysin, and at least focally they are arranged in
characteristic nests. This tumor we report was positive
for cytokeratin (Pan), cytokeratin 19, cytokeratin 5/6,
cytokeratin 7, and epithelial membrane antigen, so it is
easy to differentiate them by immunohistochemistry.
Chorioid plexus papilloma may be histologically similar
t oE L S T ,b u ti to r i g i n a t e si nt h ev e n t r i c l ea n dd o e sn o t
invade bone. To aid in the differentiation between papil-
lary tumors of endolymphatic sac and duct origin and
those arising from ectopic choroid plexus, an immuno-
histochemical study using stains for transthyretin (TTR),
cytokeratins, S-100 protein, EMA, and GFAP was car-
ried out on archival specimens of normal and neoplastic
endolymphatic sac and duct and choroid plexus epithe-
lium. Transthyretin, a marker for choroid plexus epithe-
lium, was found to show differential expression between
choroid plexus papillomas and aggressive papillary
tumors of the endolymphatic sac or duct. Therefore the
Figure 3 Immunophenotype of endolymphatic sac tumor. A. The tumor cells showed positive reactivity with cytokeratin (Pan)
(immunostaining, 400×). B. The tumor cells were positive to vimentin(immunostaining, 400×). C. The tumor cells exhibited CD56 expression
(immunostaining, 400×).D. The tumor cells exhibited NSE expression (immunostaining, 400×).
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stains appear to aid in the differentiation between intra-
cranial and intratemporal papillary tumors arising from
choroid plexus and endolymphatic sac or duct epithe-
lium [20]. Papillary ependymoma shows discohesive
growth, pseudopapillae, and perivascular pseudorosettes.
Finger like projections are lined by single or multiple
layers of cuboidal tumor cells with smooth contiguous
surfaces and with GFAP-positive tumor cell processes.
Papillary mesohyloma occurs in pelvic peritoneum, gas-
trocolic omentum, mesenterium, pleura and is positive
to CK5/6, calretinin, and vimentin. Middle ear adeno-
mas are nonpapillary, are confined to the middle ear
and mastoid, and rarely show bone destruction. Cur-
rently, considerations of metastases from thyroid, breast,
and prostate can be eliminated by
immunohistochemistry.
Treatment of ELST involves local resection of the
tumor or radical mastoidectomy alone, or in combina-
tion with radiotherapy. Early surgical excision is the best
treatment when the tumor is small. Remission may last
for years. When the tumor is large, complete excision is
nearly impossible due to the anatomic complexity of the
endolymphatic sac and distinct patterns of extension.
Local recurrence after surgery can occur. In advanced
cases radiotherapy alone may be the sole option,
although there are no studies focusing on the role of
adjuvant radiotherapy. Because endolymphatic sac
tumor is richly vascularized, some scholars suggest that
preoperative embolization may be helpful. In our case,
the mass was large, destructed the mastoid process of
the left petrous bone and extended to involve both the
left medial mastoid as well as the middle ear, so it was
difficult to extirpate surgically. After surgery, the patient
underwent gamma-knife radiosurgery for residual
tumor.
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